Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Retained Earnings (2020 - 2025)

Bolt Biotherapeutics' Retained Earnings history spans 6 years, with the latest figure at -$454.1 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 10.35% year-over-year to -$454.1 million; the TTM value through Sep 2025 reached -$454.1 million, down 10.35%, while the annual FY2024 figure was -$427.4 million, 17.33% down from the prior year.
  • Retained Earnings for Q3 2025 was -$454.1 million at Bolt Biotherapeutics, down from -$6000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $40000.0 in Q1 2025 and bottomed at -$454.1 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$179.8 million (2021), against an average of -$184.6 million.
  • The largest annual shift saw Retained Earnings crashed 1101343.48% in 2022 before it skyrocketed 211.11% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$207.0 million in 2021, then surged by 99.56% to -$919000.0 in 2022, then crashed by 39539.28% to -$364.3 million in 2023, then fell by 17.33% to -$427.4 million in 2024, then dropped by 6.25% to -$454.1 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Retained Earnings are -$454.1 million (Q3 2025), -$6000.0 (Q2 2025), and $40000.0 (Q1 2025).